Advancement in therapeutic strategies for immune-mediated oral diseases

Oldstone, 1998, Molecular mimicry and immune-mediated diseases, FASEB J, 12, 1255, 10.1096/fasebj.12.13.1255 Rittling, 2015, Osteopontin in immune-mediated diseases, J Dent Res, 94, 1638, 10.1177/0022034515605270 Vanderlugt, 2002, Epitope spreading in immune-mediated diseases: implications for immunotherapy, Nat Rev Immunol, 2, 85, 10.1038/nri724 Pacheco, 2019, Bystander activation and autoimmunity, J Autoimmun, 103, 10.1016/j.jaut.2019.06.012 Hess, 2002, Environmental chemicals and autoimmune disease: cause and effect, Toxicology, 181-182, 65, 10.1016/S0300-483X(02)00256-1 Salihoglu, 2019, Effects of childhood psychological trauma on rheumatic diseases, Eur J Rheumatol, 6, 126, 10.5152/eurjrheum.2019.18184 Lerner, 2016, The World Incidence and Prevalence of Autoimmune Diseases is Increasing, Int J Celiac Dis, 3, 151, 10.12691/ijcd-3-4-8 McGonagle, 2006, A Proposed Classification of the Immunological Diseases, PLoS Med, 3, e297, 10.1371/journal.pmed.0030297 Bascones-Martínez, 2015, Immune-mediated diseases: what can be found in the oral cavity?, Int J Dermatol, 54, 258, 10.1111/ijd.12681 Baglama, 2018, Oral manifestations of autoinflammatory and autoimmune diseases, Acta dermatovenerologica Alpina, Pannonica, Adriat, 27, 9, 10.15570/actaapa.2018.3 Suárez, 2020, Oral dysbiosis and autoimmunity: from local periodontal responses to an imbalanced systemic immunity. a review, Front Immunol, 11 Allaf, 2021, Does periodontitis play a causal role in the Systemic lupus erythematosus? A systematic review, Informatics Med Unlocked, 10.1016/j.imu.2021.100634 Fitzgibbon, 2020, The microbiota and immune-mediated diseases: Opportunities for therapeutic intervention, Eur J Immunol, 50, 326, 10.1002/eji.201948322 De Luca, 2018, The microbiome in autoimmune diseases, Clin Exp Immunol, 195, 74, 10.1111/cei.13158 Saccucci, 2018, Autoimmune diseases and their manifestations on oral cavity: diagnosis and clinical management, J Immunol Res, 2018, 1, 10.1155/2018/6061825 Mustafa, 2015, Oral mucosal manifestations of autoimmune skin diseases, Autoimmun Rev, 14, 930, 10.1016/j.autrev.2015.06.005 Williams, 2018, Clinical Pharmacology of Corticosteroids, Respir Care, 63, 655, 10.4187/respcare.06314 Gupta, 2017, Interventions for the management of oral lichen planus: a review of the conventional and novel therapies, Oral Dis, 23, 1029, 10.1111/odi.12634 Azzi, 2013, Calcineurin Inhibitors: 40 Years Later, Can't Live Without …, J Immunol, 191, 5785, 10.4049/jimmunol.1390055 McSharry, 2011, Systematic review: the role of tacrolimus in the management of Crohn's disease, Aliment Pharmacol Ther, 34, 1282, 10.1111/j.1365-2036.2011.04873.x Malecic, 2016, Tacrolimus for the management of psoriasis: clinical utility and place in therapy, Psoriasis Targets Ther, 6, 153, 10.2147/PTT.S101233 Sibbald, 2015, Retrospective review of relapse after systemic cyclosporine in children with atopic dermatitis, Pediatr Dermatol, 32, 36, 10.1111/pde.12367 Ng, 2018, A meta-analysis of cyclosporine treatment for Stevens&ndash;Johnson syndrome/toxic epidermal necrolysis, J Inflamm Res, 11, 135, 10.2147/JIR.S160964 Ogawa, 2010, Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice, Lupus, 19, 162, 10.1177/0961203309350320 Carr, 2013, Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations, Pediatr Drugs, 15, 303, 10.1007/s40272-013-0013-9 Gutfreund, 2013, Topical calcineurin inhibitors in dermatology. Part I: properties, method and effectiveness of drug use, Adv Dermatology Allergol, 3, 165, 10.5114/pdia.2013.35619 Siegfried, 2013, Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice, Am J Clin Dermatol, 14, 163, 10.1007/s40257-013-0020-1 Corrocher, 2008, Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus, J Clin Periodontol, 35, 244, 10.1111/j.1600-051X.2007.01191.x Vohra, 2016, Clinical and serological efficacy of topical calcineurin inhibitors in oral lichen planus: a prospective randomized controlled trial, Int J Dermatol, 55, 101, 10.1111/ijd.12887 Yang, 2010, The efficacy of tacrolimus 0.1% ointment in elderly patients with oral lichen planus, Chin J Geriatr Dent Siponen, 2017, Topical tacrolimus, triamcinolone acetonide, and placebo in oral lichen planus: a pilot randomized controlled trial, Oral Dis, 23, 660, 10.1111/odi.12653 Radfar, 2008, A comparative treatment study of topical tacrolimus and clobetasol in oral lichen planus, Oral Surg Oral Med Oral Pathol Oral Radiol Endodontology, 105, 187, 10.1016/j.tripleo.2007.07.029 Georgaki, 2020, A randomized clinical trial of topical dexamethasone vs. cyclosporine treatment for oral lichen planus, Med Oral Patol Oral y Cir Bucal Zhang, 2011, Biologics, an alternative therapeutic approach for oral lichen planus, J Oral Pathol Med, 40, 521, 10.1111/j.1600-0714.2011.01029.x ID, 2008, Off-label use of biologicals in the management of inflammatory oral mucosal disease, J Oral Pathol Med, 37, 575, 10.1111/j.1600-0714.2008.00693.x Georgakopoulou, 2013, Biologic agents and oral diseases – an update on clinical applications, Acta Dermatovenerol Croat, 21, 24 Choy, 2013, The problem of choice: current biologic agents and future prospects in RA, Nat Rev Rheumatol, 9, 154, 10.1038/nrrheum.2013.8 Asarch, 2009, Lichen planus–like eruptions: An emerging side effect of tumor necrosis factor-α antagonists, J Am Acad Dermatol, 61, 104, 10.1016/j.jaad.2008.09.032 Connolly, 2005, Infliximab treatment for severe orogenital ulceration in Behcet's disease, Br J Dermatol, 153, 1073, 10.1111/j.1365-2133.2005.06914.x Fivenson, 2006, Treatment of generalized lichen planus with alefacept, Arch Dermatol, 142, 10.1001/archderm.142.2.151 Chang, 2008, Alefacept for erosive lichen planus: a case series, J Drugs Dermatol, 7, 379 Recalcitrant, 2003, Recurrent aphthous stomatitis treated with etanercept, Arch Dermatol, 139, 1259, 10.1001/archderm.139.10.1259 Canizares, 2006, Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients, Arch Dermatol, 142, 10.1001/archderm.142.11.1457 Sacher, 2002, Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor α antagonist etanercept, J Am Acad Dermatol, 46, 113, 10.1067/mjd.2001.119100 Melikoglu, 2005, Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study, J Rheumatol, 32, 98 Shetty, 2009, Successful treatment of pemphigus vulgaris with etanercept in four patients, J Drugs Dermatol, 8, 940 Yarom, 2007, Etanercept for the Management of Oral Lichen Planus, Am J Clin Dermatol, 8, 121, 10.2165/00128071-200708020-00010 Joly, 2017, First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial, Lancet, 389, 2031, 10.1016/S0140-6736(17)30070-3 Fisher, 2018, Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy, Ann Rheum Dis, 77, 412, 10.1136/annrheumdis-2017-212268 Meijer, 2010, Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 62, 960, 10.1002/art.27314 Bowman, 2017, Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren's syndrome, Arthritis Rheumatol, 69, 1440, 10.1002/art.40093 Hall, 2013, Association of serum B-cell activating factor level and proportion of memory and transitional b cells with clinical response after rituximab treatment of bullous pemphigoid patients, J Invest Dermatol, 133, 2786, 10.1038/jid.2013.236 Levy, 2021, 10 Years of belimumab experience: what have we learnt?, Lupus, 30, 1705, 10.1177/09612033211028653 Furie, 2011, A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, Arthritis Rheum, 63, 3918, 10.1002/art.30613 Mariette, 2015, Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study, Ann Rheum Dis, 74, 526, 10.1136/annrheumdis-2013-203991 Quartuccio, 2016, Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study, Clin Exp Rheumatol, 34, 311 De Vita, 2015, Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study, Rheumatology, kev257, 10.1093/rheumatology/kev257 Vujevich, 2005, Treatment of severe, recalcitrant, major aphthous stomatitis with adalimumab, Cutis, 76, 129 Xiong, 2009, The efficacy of topical intralesional BCG-PSN injection in the treatment of erosive oral lichen planus: a randomized controlled trial, J Oral Pathol Med, 38, 551, 10.1111/j.1600-0714.2009.00796.x Mannucci, 2021, Nutraceuticals against oxidative stress in autoimmune disorders, Antioxidants, 10, 261, 10.3390/antiox10020261 Choonhakarn, 2007, The efficacy of aloe vera gel in the treatment of oral lichen planus: a randomized controlled trial, Br J Dermatol, 158, 573, 10.1111/j.1365-2133.2007.08370.x Mansour, 2014, Clinical efficacy of new aloe vera- and myrrh-based oral mucoadhesive gels in the management of minor recurrent aphthous stomatitis: a randomized, double-blind, vehicle-controlled study, J Oral Pathol Med, 43, 405, 10.1111/jop.12130 Kia, 2020, New concentration of curcumin orabase in recurrent aphthous stomatitis: a randomized, controlled clinical trial, J Herb Med, 22, 10.1016/j.hermed.2020.100336 Halim, 2013, Novel material in the treatment of minor oral recurrent aphthous stomatitis, Int Med J Al-Maweri, 2020, Efficacy of curcumin for recurrent aphthous stomatitis: a systematic review, J Dermatolog Treat, 1 Kia, 2015, Comparative efficacy of topical curcumin and triamcinolone for oral lichen planus: a randomized, controlled clinical trial, J Dent (Tehran), 12, 789 Lv, 2019, Clinical safety and efficacy of curcumin use for oral lichen planus: a systematic review, J Dermatolog Treat, 30, 605, 10.1080/09546634.2018.1543849 Pandharipande, 2019, To evaluate efficiency of curcumin and honey in patients with recurrent aphthous stomatitis: a randomized clinical controlled trial, Int J Res Rev, 6, 449 Oskuee, 2012, Comparison the efficacy of honey mouthwash with hydrogen peroxide mouthwash on oral lesions healing in patients with Pemphigus .Abstract Background Pemphigus is a rare and potentially life-threatening disease. It produces blisters in the skin and mucous m, Adv Nurs Midwifery, 21, 48 Sanatkhani, 2014, Effect of cedar honey in the treatment of oral lichen planus, Iran J Otorhinolaryngol, 26, 151 Babaee, 2010, The efficacy of a paste containing Myrtus communis (Myrtle) in the management of recurrent aphthous stomatitis: a randomized controlled trial, Clin Oral Investig, 14, 65, 10.1007/s00784-009-0267-3 Filho, 2000, Safety and efficacy ofEupatorium laevigatum paste as therapy for buccal aphthae: Randomized, double-blind comparison with triamcinolone 0.1% orabase, Adv Ther, 17, 272, 10.1007/BF02850010 Othman, 2016, The effect of diode laser and topical steroid on serum level of TNF-alpha in oral lichen planus patients, J Clin Exp Dent, 10.4317/jced.52665 Elshenawy, 2015, A comparative evaluation of low-level laser and topical steroid therapies for the treatment of erosive-atrophic lichen planus, Open Access Maced J Med Sci, 3, 462, 10.3889/oamjms.2015.072 Al-Maweri, 2017, Efficacy of low-level laser therapy in management of symptomatic oral lichen planus: a systematic review, Lasers Med Sci, 32, 1429, 10.1007/s10103-017-2233-7 Minicucci, 2012, Low-level laser therapy on the treatment of oral and cutaneous pemphigus vulgaris: case report, Lasers Med Sci, 27, 1103, 10.1007/s10103-012-1101-8 Yousefi, 2017, The effect of low level laser therapy on pemphigus vulgaris lesions: a pilot study, J Lasers Med Sci, 8, 177, 10.15171/jlms.2017.32 Yilmaz, 2010, Low-level laser therapy in the treatment of mucous membrane pemphigoid: a promising procedure, J Periodontol, 81, 1226, 10.1902/jop.2010.100095 Gomes, 2020, Treatment of mucous membrane pemphigoid with low-level laser therapy, Oral Surg Oral Med Oral Pathol Oral Radiol., 10.1016/j.oooo.2019.06.056 Cafaro, 2012, Low-level laser therapy for oral mucous membrane pemphigoid, Lasers Med Sci, 27, 1247, 10.1007/s10103-012-1137-9 Yang, 2021, Application of photodynamic therapy in immune-related diseases, Photodiagnosis Photodyn Ther, 34, 10.1016/j.pdpdt.2021.102318 Saleh, 2020, Could photodynamic therapy be utilized as a treatment modality for oral lichen planus?, Photodiagnosis Photodyn Ther, 30, 10.1016/j.pdpdt.2020.101677 Sulewska, 2019, A clinical evaluation of efficacy of photodynamic therapy in treatment of reticular oral lichen planus: A case series, Photodiagnosis Photodyn Ther, 25, 50, 10.1016/j.pdpdt.2018.11.009 Bakos, 2009, Photodynamic therapy: a useful adjunct therapy for recalcitrant ulceration in pemphigus vulgaris, J Eur Acad Dermatology Venereol, 23, 599, 10.1111/j.1468-3083.2008.02976.x Ruiz-Rodrigueza, 2002, Photodynamic therapy with 5-aminolevulinic acid for recalcitrant familial benign pemphigus (Hailey-Hailey disease), J Am Acad Dermatol, 47, 740, 10.1067/mjd.2002.124802 Yan, 2015, Successful treatment of hailey-hailey disease with aminolevulinic acid photodynamic therapy, Ann Dermatol, 27, 222, 10.5021/ad.2015.27.2.222 Zhou, 2017, Pemphigus vulgaris induced by 5-aminolaevulinic acid-based photodynamic therapy, Photodiagnosis Photodyn Ther, 19, 156, 10.1016/j.pdpdt.2017.05.014 Rakvit, 2011, Localized bullous pemphigoid induced by photodynamic therapy, Photodermatol Photoimmunol Photomed, 27, 251, 10.1111/j.1600-0781.2011.00609.x Kluger, 2017, Photodynamic therapy-triggered bullous pemphigoid, Int J Dermatol, 56, e41, 10.1111/ijd.13387 Ferguson, 2018, Kinase inhibitors: the road ahead, Nat Rev Drug Discov, 17, 353, 10.1038/nrd.2018.21 Roskoski, 2020, Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update, Pharmacol Res, 152, 10.1016/j.phrs.2019.104609 Kontzias, 2012, Kinase inhibitors in the treatment of immune-mediated disease, F1000 Med Rep, 4, 10.3410/M4-5 Virtanen A, 2019, Selective JAKinibs: prospects in inflammatory and autoimmune diseases, BioDrugs, 33, 15, 10.1007/s40259-019-00333-w Nash, 2021, Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement, Ann Rheum Dis, 80, 71, 10.1136/annrheumdis-2020-218398 Fleischmann, 2017, Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment, Arthritis Rheumatol, 69, 506, 10.1002/art.39953 Lee, 2014, Tofacitinib versus methotrexate in rheumatoid arthritis, N Engl J Med, 370, 2377, 10.1056/NEJMoa1310476 Smolen, 2019, Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study, Lancet, 393, 2303, 10.1016/S0140-6736(19)30419-2 Ports, 2013, A randomized phase 2a efficacy and safety trial of the topical <scp>J</scp>anus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis, Br J Dermatol, 169, 137, 10.1111/bjd.12266 Papp, 2016, A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis, Br J Dermatol, 174, 1266, 10.1111/bjd.14403 Wallace, 2018, Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial, Lancet, 392, 222, 10.1016/S0140-6736(18)31363-1 Szilveszter, 2019, Tyrosine Kinases in autoimmune and inflammatory skin diseases, Front Immunol, 10, 10.3389/fimmu.2019.01862 Deng, 2016, Targeting syk in autoimmune rheumatic diseases, Front Immunol, 7, 10.3389/fimmu.2016.00078 Markham, 2018, Fostamatinib: first global approval, Drugs, 78, 959, 10.1007/s40265-018-0927-1 Tanaka, 2021, Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study, Rheumatology, 60, 2884, 10.1093/rheumatology/keaa732 Murrell, 2021, Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*, Br J Dermatol, 185, 745, 10.1111/bjd.20431 Piali, 2017, Cenerimod, a novel selective S1P 1 receptor modulator with unique signaling properties, Pharmacol Res Perspect, 5, e00370, 10.1002/prp2.370 Hermann, 2019, First use of cenerimod, a selective S1P 1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study, Lupus Sci Med, 6, 10.1136/lupus-2019-000354 Gerossier, 2021, Cenerimod, a selective S1P1 receptor modulator, improves organ-specific disease outcomes in animal models of Sjögren's syndrome, Arthritis Res Ther, 23, 289, 10.1186/s13075-021-02673-x Vaclavkova, 2014, Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial, Lancet, 384, 2036, 10.1016/S0140-6736(14)60803-5 Raj, 2021, Assessing the effect of human dental pulp mesenchymal stem cell secretome on human oral, breast, and melanoma cancer cell lines, Saudi J Biol Sci, 28, 6556, 10.1016/j.sjbs.2021.07.029 Raj, 2021, The growth factors and cytokines of dental pulp mesenchymal stem cell secretome may potentially aid in oral cancer proliferation, Molecules, 26, 5683, 10.3390/molecules26185683 Sayed, 2021, Role of stem cells in augmenting dental implant osseointegration: a systematic review, Coatings, 11, 1035, 10.3390/coatings11091035 Fageeh, 2021, Viability of quercetin-induced dental pulp stem cells in forming living cellular constructs for soft tissue augmentation, J Pers Med, 11, 430, 10.3390/jpm11050430 Jiang, 2020, Immune modulation by mesenchymal stem cells, Cell Prolif, 53, 10.1111/cpr.12712 Weiss, 2019, Immunomodulation by Mesenchymal Stem Cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs, Front Immunol, 10, 10.3389/fimmu.2019.01191 González, 2009, Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells, Arthritis Rheum, 60, 1006, 10.1002/art.24405 Youd, 2010, Allogeneic mesenchymal stem cells do not protect NZB × NZW F1 mice from developing lupus disease, Clin Exp Immunol, 161, 176, 10.1111/j.1365-2249.2010.04158.x Sun, 2009, Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans, Stem Cells, 27, 1421, 10.1002/stem.68 Dhanapal, 2017, Interference RNA in immune-mediated oral diseases – minireview, Cent Eur J Immunol, 3, 301, 10.5114/ceji.2017.70974 Liu, 2018, RNA Interference Ex Vivo, In. Methods Mol Biol, 1868, 129, 10.1007/978-1-4939-8802-0_13